Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy Using 131I-omburtamab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

Trial Profile

A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy Using 131I-omburtamab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 22 Jan 2019

At a glance

  • Drugs Omburtamab-I-131 (Primary)
  • Indications Neuroblastoma
  • Focus Therapeutic Use
  • Sponsors Y-mAbs Therapeutics
  • Most Recent Events

    • 30 Oct 2018 Status changed from not yet recruiting to recruiting.
    • 02 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 1 Oct 2018.
    • 28 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top